Universal Health Services stock rating reiterated by UBS on mixed outlook

UBS reaffirmed its Buy rating on Universal Health Services (UHS) with a $280 price target, citing the company's strong financial health and profitability despite challenges in its behavioral health segment. While UHS's Q1 2025 earnings per share beat expectations at $4.80, revenue missed forecasts at $4.1 billion; however, the company maintained its full-year earnings guidance, supported by robust pricing growth in behavioral health and solid acute care volumes. Analysts have mixed ratings on UHS, acknowledging staffing pressures but also noting positive trends in inpatient psychiatric care, with the company targeting 2.5-3% same-store patient day growth long-term.

Analysis

Universal Health Services (UHS) received a reaffirmed Buy rating and a $280.00 price target from UBS, suggesting substantial upside from its current $171.76 trading price, supported by InvestingPro's assessment of 'GREAT' financial health and robust profitability metrics. The company demonstrated solid operational performance with 9.73% revenue growth, an attractive P/E ratio of 10.21, and an impressive 10% free cash flow yield, alongside a 23-year history of dividend payments. For Q1 2025, UHS reported an earnings per share of $4.80, surpassing analyst expectations of $4.36, though revenue of $4.1 billion fell short of the anticipated $4.16 billion; crucially, full-year earnings guidance was maintained. While acute care volumes are meeting expectations, the behavioral health segment faces challenges, with adjusted patient days declining 0.3% in Q1 2025, making the targeted 2.5-3% same-store patient day growth for the full year difficult, as it would necessitate an average 3.4% growth from Q2-Q4. However, robust behavioral pricing growth of 5.8% in Q1 provides a potential offset, with UBS suggesting this could be sufficient to meet full-year same-store revenue targets even if volumes lag. Other analysts offer mixed views: Morgan Stanley holds an Equalweight rating, citing solid acute utilization and potential for a catch-up trade, while Cantor Fitzgerald maintains a Neutral rating, noting staffing pressures but acknowledging strong pricing discipline. Staffing challenges persist, particularly in inpatient acute care, though these are reportedly being managed without significant increases in bonus incentives.

Key Decisions for Investors

• Evaluate the significant upside potential indicated by UBS's $280 price target against the current trading price, considering UHS's strong financial health, attractive P/E ratio of 10.21, and 10% free cash flow yield as potential indicators of undervaluation.
• Closely monitor behavioral health patient day growth in upcoming quarters, as achieving the targeted 2.5-3% annual growth requires a substantial acceleration from the Q1 decline, and assess the continued strength of pricing (5.8% in Q1) to offset volume shortfalls.
• Consider the balance between positive factors such as the Q1 EPS beat, maintained full-year guidance, and consistent dividend payments, against risks including mixed analyst ratings from firms like Morgan Stanley and Cantor Fitzgerald, ongoing staffing pressures, and the recent Q1 revenue miss before adjusting positions.